Results 21 to 30 of about 25,204 (165)

Applications of genetic-epigenetic tissue mapping for plasma DNA in prenatal testing, transplantation and oncology

eLife, 2021
We developed genetic-epigenetic tissue mapping (GETMap) to determine the tissue composition of plasma DNA carrying genetic variants not present in the constitutional genome through comparing their methylation profiles with relevant tissues.
Wanxia Gai, Ze Zhou, Sean Agbor-Enoh, Xiaodan Fan, Sheng Lian, Peiyong Jiang, Suk Hang Cheng, John Wong, Stephen L Chan, Moon Kyoo Jang, Yanqin Yang, Raymond HS Liang, Wai Kong Chan, Edmond SK Ma, Tak Y Leung, Rossa WK Chiu, Hannah Valantine, KC Allen Chan, YM Dennis Lo   +18 more
doaj   +1 more source

Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples

Cancers, 2022
Liquid biopsy has improved significantly over the last decade and is attracting attention as a tool that can complement tissue biopsy to evaluate the genetic landscape of solid tumors. In the present study, we evaluated the usefulness of liquid biopsy in daily oncology practice in different clinical contexts.
Josep Gumà, Karla Peña, Francesc Riu, Carmen Guilarte, Anna Hernandez, Clara Lucía, Francisca Martínez-Madueño, Maria José Miranda, Inés Cabezas, Marc Grifoll, Sergio Peralta, Sara Serrano, Félix Muñoz, Lola Delamo, Barbara Roig, Joan Borràs, Joan Badia, Marta Rodriguez-Balada, David Parada   +18 more
openaire   +2 more sources

Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer

Cancer Biology & Medicine, 2021
Objective: Anlotinib is a novel tyrosine kinase inhibitor blocking angiogenesis. This study was performed to assess the efficacy and safety of anlotinib in patients with metastatic breast cancer.
Nanlin Hu, Yiran Si, Jian Yue, Tingting Sun, Xue Wang, Zhuqing Jia, Songlin Gao, Qiao Li, Yang Shao, Jiayu Wang, Yang Luo, Fei Ma, Binghe Xu, Peng Yuan   +13 more
doaj   +1 more source

Plasma ctDNA TP53 Mutation and Breast Cancer Prognosis: A Systematic Review and Meta-Analysis

Xiehe Yixue Zazhi
ObjectiveTo analyze the association between plasma circulating tumor DNA (ctDNA) TP53 mutation status and survival outcomes in breast cancer patients.MethodsPubMed, Embase, and the Cochrane Library were searched for relevant literature published between ...
FAN Hao, LIANG Annan, ZOU Wei, GAO Guangxi, LIU Lijin, LIU Fei, ZHAO Lina, WU Zhihong   +7 more
doaj   +1 more source

The Prognostic Impact of Early ctDNA Kinetics in Metastatic Pancreatic Cancer Using the ctDNA-RECIST [PDF]

Clinical Cancer Research
Abstract Purpose: Changes in ctDNA levels during systemic treatment may predict treatment efficacy in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), but quantitative response criteria are not yet established. This study evaluates our recently proposed ctDNA-RECIST.
Mette M. Steiniche, Sidsel C. Lindgaard, Inna M. Chen, Julia S. Johansen, Rikke F. Andersen, Torben F. Hansen, Lars H. Jensen, Louise S. Rasmussen, Malene W. Johansen, Morten Ladekarl, Anders K.M. Jakobsen, Karen-Lise G. Spindler   +11 more
openaire   +7 more sources

Molecular clustering on ctDNA improves the prognostic stratification of patients with DLBCL compared with ctDNA levels

Blood Advances
Abstract Circulating tumor DNA (ctDNA) levels can help predict outcomes in diffuse large B-cell lymphoma (DLBCL), but its integration with DLBCL molecular clusters remains unexplored. Using the LymphGen tool in 77 DLBCL cases with both ctDNA and tissue biopsy, a 95.8% concordance rate in molecular cluster assignment
Riccardo Moia, Donatella Talotta, Lodovico Terzi Di Bergamo, Mohammad Almasri, Riccardo Dondolin, Matin Salehi, Chiara Cosentino, Roberta Soscia, Irene Della Starza, Alessio Bruscaggin, Annalisa Andorno, Francesca Mercalli, Stefania Cresta, Riccardo Bomben, Tamara Bittolo, Filippo Vit, Pietro Bulian, Antonella Zucchetto, Riccardo Bruna, Giulia Maria Rivolta, Mattia Schipani, Eleonora Secomandi, Sreekar Kogila, Matteo Bellia, Samir Mouhssine, Jana Nabki, Bashar Al Deeban, Joseph Ghanej, Luca Cividini, Nawar Maher, Federica Melle, Giovanna Motta, Monica Leutner, Angela Lorenzi, Abdurraouf Mokhtar Mahmoud, Wael Al Essa, Clara Deambrogi, Silvia Rasi, Luigi Petrucci, Renzo Luciano Boldorini, Alice Di Rocco, Ilaria Del Giudice, Michele Spina, Stefano Palazzolo, Fabio Canal, Vincenzo Canzonieri, Maurizio Martelli, Stefano Pileri, Valter Gattei, Robin Foà, Davide Rossi, Gianluca Gaidano   +51 more
openaire   +6 more sources

Pan-cancer screening by circulating tumor DNA (ctDNA) – recent breakthroughs and chronic pitfalls

Journal of Laboratory Medicine, 2022
Early detection is crucial for optimal treatment and prognosis of cancer. New approaches for pan-cancer screening comprise the comprehensive characterization of circulating tumor DNA (ctDNA) in plasma by next generation sequencing and molecular profiling
Holdenrieder Stefan, Ungerer Vida, Oberhofer Angela, Bronkhorst Abel Jacobus   +3 more
doaj   +1 more source

New Frontiers in Diagnosis and Therapy of Circulating Tumor Markers in Cerebrospinal Fluid In Vitro and In Vivo

Cells, 2019
One of the greatest challenges in neuro-oncology is diagnosis and therapy (theranostics) of leptomeningeal metastasis (LM), brain metastasis (BM) and brain tumors (BT), which are associated with poor prognosis in patients.
Olga A. Sindeeva, Roman A. Verkhovskii, Mustafa Sarimollaoglu, Galina A. Afanaseva, Alexander S. Fedonnikov, Evgeny Yu. Osintsev, Elena N. Kurochkina, Dmitry A. Gorin, Sergey M. Deyev, Vladimir P. Zharov, Ekaterina I. Galanzha   +10 more
doaj   +1 more source

Outcomes with liquid biopsy to determine the EGFR mutation status in poor performance status, biopsy-ineligible, advanced NSCLC patients

Cancer Research, Statistics, and Treatment, 2019
Background: Outcomes based on liquid biopsy in poor performance, older, biopsy-ineligible advanced non-small cell lung cancer (NSCLC) patients are unknown.
Avinash Pandey, Sarjana Dutt, Anjana Singh, Amit Kumar, Shivkant Singh   +4 more
doaj   +1 more source

Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis

Frontiers in Oncology, 2022
Cancer cells release nucleic acids, freely or associated with other structures such as vesicles into body fluids, including blood. Among these nucleic acids, circulating tumor DNA (ctDNA) has emerged as a minimally invasive biomarker for tumor molecular ...
Estela Sánchez-Herrero, Estela Sánchez-Herrero, Roberto Serna-Blasco, Lucia Robado de Lope, Víctor González-Rumayor, Atocha Romero, Atocha Romero, Mariano Provencio, Mariano Provencio   +8 more
doaj   +1 more source